Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenezumab in prodromal to mild Alzheimer's disease (China extension of CREAD)
CTR20180392Phase 3Suspended
- Sponsor
- Roche
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of crenezumab in Alzheimer's disease (AD), sponsored by Roche. Started Apr 2018; status: suspended.
02
Drugs
crenezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20180392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180392.